135 related articles for article (PubMed ID: 6507373)
1. A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
Rubin J; Schutt AJ; O'Connell MJ; Gertz MA; Moertel CG
Am J Clin Oncol; 1984 Oct; 7(5):523-5. PubMed ID: 6507373
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Chiuten DF; Valdivieso M; Bedikian A; Bodey GP; Freireich EJ
Cancer Treat Rep; 1985 Jun; 69(6):611-3. PubMed ID: 4016768
[TBL] [Abstract][Full Text] [Related]
3. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
Jodrell DI; Oster W; Kerr DJ; Canney PA; Yosef H; Steward WP; Kaye SB; Cassidy J
Eur J Cancer; 1994; 30A(7):950-5. PubMed ID: 7946590
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
O'Connell MJ; Moertel CG; Rubin J; Hahn RG; Kvols LK; Schutt AJ
J Clin Oncol; 1984 Oct; 2(10):1133-8. PubMed ID: 6491697
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma.
O'Connell MJ; Rubin J; Schutt AJ; Moertel CG; Kvols LK
Cancer Treat Rep; 1983 Dec; 67(12):1141-2. PubMed ID: 6360350
[No Abstract] [Full Text] [Related]
9. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
Carroll DS; Gralla RJ; Kemeny NE
Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
[No Abstract] [Full Text] [Related]
10. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Buroker TR; Moertel CG; Fleming TR; Everson LK; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Klaassen DJ; Laurie JA
J Clin Oncol; 1985 Dec; 3(12):1624-31. PubMed ID: 2933492
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Ardalan B; Singh G; Silberman H
J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
[TBL] [Abstract][Full Text] [Related]
13. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Chan TC; Markman M; Cleary S; Howell SB
Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
[TBL] [Abstract][Full Text] [Related]
14. Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Muggia FM; Camacho FJ; Kaplan BH; Green MD; Greenwald ES; Wernz JC; Engstrom PF
Cancer Treat Rep; 1987 Mar; 71(3):253-6. PubMed ID: 3815391
[TBL] [Abstract][Full Text] [Related]
15. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
[TBL] [Abstract][Full Text] [Related]
16. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Chiuten DF; Miller A; Valdivieso M; Loo TL; Bedikian A; Bodey GP; Benvenuto JA; Freireich EJ
Am J Clin Oncol; 1985 Aug; 8(4):332-5. PubMed ID: 4083263
[TBL] [Abstract][Full Text] [Related]
17. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
Köhne CH; Harstrick A; Hiddemann W; Schöffski P; Wilke H; Bokemeyer C; Dörken B; Schmoll HJ
Eur J Cancer; 1997 Oct; 33(11):1896-9. PubMed ID: 9470854
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
Wadler S; Gleissner B; Hilgenfeld RU; Thiel E; Haynes H; Kaleya R; Rozenblit A; Kreuser ED
Eur J Cancer; 1996 Jun; 32A(7):1254-6. PubMed ID: 8758262
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
O'Dwyer PJ; Paul AR; Walczak J; Weiner LM; Litwin S; Comis RL
J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
[TBL] [Abstract][Full Text] [Related]
20. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Harstrick A; Köhne CH; Hiddemann W; Preusser P; Strumberg D; Berns T; Seeber S; Wilke H; Schmoll HJ
Ann Oncol; 1997 Sep; 8(9):917-8. PubMed ID: 9358946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
